ANO1 amplified in >35% EC (esophageal carcinoma, ESCA), >6% GC (stomach adenocarcinoma, STAD), and >5% cholangiocarcinoma, and also frequently amplified in other non‐GI cancers, including head and neck squamous cell carcinoma, lung squamous cell carcinoma, breast invasive carcinoma, and bladder urothelial carcinoma (Figure S2A, Supporting Information). Here, ANO1 is linked to invasive breast carcinoma.